Yahoo Finance

Non-Cystic Fibrosis Bronchiectasis Pipeline Insight: Over 15 Companies are Progressing Through to Improve the Treatment Landscape | DelveInsight

DelveInsight’s 'Non-Cystic Fibrosis Bronchiectasis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline non-cystic fibrosis bronchiectasis therapies in various stages of ...
Yahoo Finance

Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight

New York, USA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight Insmed’s BRINSUPRI (brensocatib) has ...
BioSpace

Insmed Jumps on ‘Blowout’ Sales Beat for Bronchiectasis Drug Brinsupri

Insmed's freshly approved lung condition drug soared past sales expectations for 2025, netting $144.6 million in its first ...
Mena FN

Non Cystic Fibrosis Bronchiectasis Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, And Companies

Brensocatib (INS1007 or AZD7986) is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such ...
Mena FN

Non-Cystic Fibrosis Bronchiectasis Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, And FDA Approvals By Delveinsight Insmed Inc, Astrazeneca, Zambon ...

(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Non-Cystic Fibrosis Bronchiectasis pipeline constitutes 15+ key companies continuously working towards ...
Monthly Prescribing Reference

Brensocatib Gets Priority Review for Non-Cystic Fibrosis Bronchiectasis

A Prescription Drug User Fee Act target date of August 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...
Yahoo Finance

Non-Cystic Fibrosis Bronchiectasis Market Research 2025-2035, Competitive Analysis of AstraZeneca, Sanofi, Insmed, Boehringer Ingelheim, Zambon, Chiesi, Haisco, Regeneron

Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Non-Cystic Fibrosis Bronchiectasis Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035" report has ...
Medscape

Bronchiectasis, Cystic Fibrosis, Asthma Risk Factors for Aspergillosis

December 17, 2010 (Dubai, United Arab Emirates) — Aspergillus infects as many as 10% of patients with bronchiectasis. The fungus has a unique self-defense mechanism against phagocytes, allowing it to ...
The Globe and Mail

Non-Cystic Fibrosis Bronchiectasis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Insmed Inc, AstraZeneca ...

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Non-Cystic Fibrosis Bronchiectasis pipeline constitutes 16+ key companies continuously working towards developing 17+ Non ...
The Globe and Mail

Non-Cystic Fibrosis Bronchiectasis Market Expected to Gain Momentum Through 2034, According to DelveInsight | Insmed, AstraZeneca, Zambion, The Marcus Foundation, Chiesi ...

The Key Non-Cystic Fibrosis Bronchiectasis Companies in the market include - Boehringer Ingelheim, Zambon, Insmed, AstraZeneca, Zambion, The Marcus Foundation, Inc ...
The American Journal of Managed Care

Case Report Describes Bronchiectasis in Patient With NPDB

The case suggests lung transplantation can be a feasible option for patients with lung involvement. A new case report is adding complexity to scientists’ understanding of a rare lysosomal storage ...